Achieving the composite endpoint of glycated haemoglobin 7.0 no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme

摘要

AimTo compare the effectiveness of dulaglutide 1.5 and 0.75 mg with active comparators and placebo with regard to a composite endpoint of glycated haemoglobin (HbA1c), weight and hypoglycaemia, using post hoc analyses.